A detailed history of Blueshift Asset Management, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Blueshift Asset Management, LLC holds 1,852 shares of MDGL stock, worth $560,544. This represents 0.1% of its overall portfolio holdings.

Number of Shares
1,852
Holding current value
$560,544
% of portfolio
0.1%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$212.22 - $292.96 $393,031 - $542,561
1,852 New
1,852 $393,000
Q2 2023

Aug 15, 2023

BUY
$203.88 - $312.0 $164,735 - $252,096
808 Added 34.66%
3,139 $725,000
Q1 2023

May 12, 2023

BUY
$231.06 - $307.08 $538,600 - $715,803
2,331 New
2,331 $564,000
Q2 2022

Aug 12, 2022

SELL
$58.04 - $100.2 $252,357 - $435,669
-4,348 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$55.89 - $101.89 $243,009 - $443,017
4,348 New
4,348 $427,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.18B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Blueshift Asset Management, LLC Portfolio

Follow Blueshift Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Blueshift Asset Management, LLC with notifications on news.